Adhera Therapeutics Expands Relationship with Melior Pharmaceuticals I, Adds NASH and Pulmonary Inflammation to Portfolio of Target Indications
October 20, 2021 09:35 ET
|
Adhera Therapeutics, Inc.
Adhera has an exclusive license agreement with Melior Pharmaceuticals I, pursuant to which Adhera is advancing MLR-1023 (tolimidone) into Phase 2 trials for Type 1 diabetesThe agreement has been...
Inventiva annonce la présentation de cinq abstracts scientifiques lors du The Liver Meeting™ 2021 organisé par l’AASLD
October 18, 2021 16:00 ET
|
INVENTIVA
Quatre présentations par poster confirment les effets bénéfiques de lanifibranor sur des composants clés de la NASH faisant suite à des analyses supplémentaires réalisées sur les résultats de l'étude...
Inventiva announces the presentation of five scientific abstracts at the AASLD The Liver Meeting™ 2021
October 18, 2021 16:00 ET
|
INVENTIVA
Four poster presentations add to the evidence of the beneficial effects of lanifibranor therapy on key components of NASH, following further sub-analyses of Inventiva’s NATIVE Phase IIb clinical trial...
Sonic Incytes Showcases Velacur™ at ACG 2021
October 13, 2021 10:00 ET
|
Sonic Incytes Medical Corp.
VANCOUVER, British Columbia, Oct. 13, 2021 (GLOBE NEWSWIRE) -- In recognition of Liver Awareness Month this October, Sonic Incytes Medical Corp. is pleased to showcase VelacurTM, the first handheld...
Therathechnologies présentera au H.C. Wainwright 5th Annual Nash Investor Conference
October 06, 2021 08:30 ET
|
Theratechnologies
MONTRÉAL, 06 oct. 2021 (GLOBE NEWSWIRE) -- Theratechnologies inc. (Theratechnologies) (TSX : TH) (NASDAQ : THTX), une société biopharmaceutique axée sur le développement et la commercialisation...
Theratechnologies to Present at the H.C. Wainwright 5th Annual Nash Investor Conference
October 06, 2021 08:30 ET
|
Theratechnologies
MONTREAL, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of...
Madrigal Pharmaceuticals Announces Support of Fatty Liver Foundation’s Screening Fund to Improve Diagnosis and Staging of Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH)
October 04, 2021 06:50 ET
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for fatty liver diseases,...
Inventiva annonce sa participation à plusieurs conférences investisseurs en octobre 2021
September 28, 2021 16:00 ET
|
INVENTIVA
Daix (France), Long Island City (New York, Etats-Unis), le 28 septembre 2021 – Inventiva (Euronext Paris et Nasdaq : IVA), société biopharmaceutique spécialisée dans le développement clinique de...
Inventiva announces participation at several investor conferences in October 2021
September 28, 2021 16:00 ET
|
INVENTIVA
Daix (France), Long Island City (New York, United States), September 28, 2021 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of...
Inventiva announces FDA decision that Fast Track designation granted to lanifibranor in NASH encompasses the treatment of NASH with compensated cirrhosis
September 21, 2021 16:00 ET
|
INVENTIVA
The FDA decision follows the Company’s Fast Track designation request for lanifibranor in NASH with compensated cirrhosis filed in August 2021 Daix (France), Long Island City (New York,...